Alzheimer disease


Alzheimer disease
Degenerative brain disorder.

It occurs in middle to late adult life, destroying neurons and connections in the cerebral cortex and resulting in significant loss of brain mass. The most common form of dementia, Alzheimer disease progresses from short-term memory impairment to further memory loss; deterioration of language, perceptual, and motor skills; mood instability; and, in advanced stages, unresponsiveness, with loss of mobility and control of body functions; death typically ensues in 5–10 years. Originally described in 1906 by the German neuropathologist Alois Alzheimer (1864–1915) with reference to a 55-year-old person and regarded as a presenile dementia, Alzheimer disease is now recognized as accounting for much of the senile dementia once thought normal with aging. The 10% of cases that begin before age 60 result from an inherited mutation. Neuritic plaques and neurofibrillary tangles in the brain on autopsy are the primary features used for diagnosis. No cure has been found. Most treatment targets the depression, behavioral problems, and sleeplessness that often accompany the disease.

* * *

      degenerative brain disorder that develops in mid- to late adulthood. It results in a progressive and irreversible decline in memory and a deterioration of various other cognitive abilities. The disease is characterized by the destruction of nerve cells and neural connections in the cerebral cortex of the brain and by a significant loss of brain mass. The disease was first described in 1906 by Alois Alzheimer, a German neuropathologist.

      Alzheimer disease is the most common form of dementia. The disease develops differently among individuals, suggesting that more than one pathologic process may lead to the same outcome. The first symptom marking the transition from normal aging to Alzheimer disease is forgetfulness. This transitional stage, known as amnestic mild cognitive impairment (MCI), is characterized by noticeable dysfunction in memory with retention of normal cognitive ability in judgment, reasoning, and perception. As amnestic MCI progresses to Alzheimer disease, memory loss becomes more severe, and language, perceptual, and motor skills deteriorate. Mood becomes unstable, and the individual tends to become irritable and more sensitive to stress and may become intermittently angry, anxious, or depressed. In advanced stages, the individual becomes unresponsive and loses mobility and control of body functions; death ensues after a disease course lasting from 2 to 20 years.

      About 10 percent of those who develop the disease are younger than 60 years of age. These cases, referred to as early-onset familial Alzheimer disease, result from an inherited genetic mutation. The majority of cases of Alzheimer disease, however, develop after age 60 (late-onset); they usually occur sporadically—i.e., in individuals with no family history of the disease—although a genetic factor has been identified that is thought to predispose these individuals to the disorder.

      The presence of neuritic plaques and neurofibrillary tangles in the brain are used to diagnose Alzheimer disease in autopsy. Neuritic plaques—also called senile, dendritic, or amyloid plaques—consist of deteriorating neuronal material surrounding deposits of a sticky protein called beta-amyloid. This protein is derived from a larger molecule called amyloid precursor protein, which is a normal component of nerve cells. Neurofibrillary tangles are twisted protein fibres located within nerve cells. These fibres consist of a protein, called tau, that normally occurs in neurons. When incorrectly processed, tau molecules clump together and form tangles. Both neuritic plaques and neurofibrillary tangles, which also may be found in smaller amounts in the brains of healthy elderly persons, are thought to interfere in some way with normal cellular functioning. However, it is not known whether the plaques and tangles are a cause or a consequence of the disease.

      Other features have been noted in the brains of many persons with Alzheimer disease. One feature is a deficiency of the neurotransmitter acetylcholine; neurons containing acetylcholine play an important role in memory. A second feature is abnormal insulin signaling in the brain. Under normal conditions, insulin binds to insulin receptors, which are expressed in great numbers on the membranes of neurons, to facilitate neuronal uptake of glucose, which the brain depends upon to carry out its many functions. However, neurons in the brains of patients with Alzheimer disease have very few, if any, insulin receptors and therefore are resistant to the actions of insulin. As a result of the inability of insulin to bind to the neurons, it accumulates in the blood serum, leading to a condition known as hyperinsulinemia (abnormally high serum levels of insulin). Hyperinsulinemia in the brain is suspected to stimulate inflammation that in turn stimulates the formation of neuritic plaques. Abnormal insulin signaling in the brain has also been associated with nerve cell dysfunction and death, decreased levels of acetylcholine, and decreased levels of transthyretin, a protein that normally binds to and transports beta-amyloid proteins out of the brain.

      Underlying genetic defects have been identified for both late- and early-onset cases of Alzheimer disease. A defect in the gene that codes for amyloid precursor protein may increase the production or deposition of beta-amyloid, which forms the core of neuritic plaques. This gene, however, is responsible for only 2 to 3 percent of all early-onset cases of the disease; the remainder are attributed to two other genes. A defect in the gene that directs production of apolipoprotein E (ApoE), which is involved in cholesterol transport, may be a factor in the majority of late-onset Alzheimer cases. There are three forms of this gene—ApoE2, ApoE3, and ApoE4—one of which, ApoE4, is associated with a higher risk of disease.

      There is no cure for Alzheimer disease; however, there are several therapeutic agents that can be used to slow disease progression or to alleviate symptoms. In roughly 50 percent of patients, the progression of amnestic MCI can be delayed for about one year by drugs called acetylcholinesterase inhibitors (or anticholinesterases (anticholinesterase)). These drugs, which include galantamine, donepezil, rivastigmine, and tacrine (no longer marketed but still available), work by slowing the breakdown of acetylcholine. Common side effects of acetylcholinesterase inhibitors include nausea, vomiting, and diarrhea; a common and serious side effect of tacrine is liver toxicity. Symptoms of Alzheimer disease can be reduced in some patients by the drug memnatine, which decreases abnormal brain activity by blocking the binding of glutamate (an excitatory neurotransmitter) to certain receptors in the brain. While this drug can improve cognition and enable patients to become more engaged in daily activities, it may cause certain patients to become unusually agitated or delusional. Other treatments aim to control the depression, behavioral problems, and insomnia that often accompany the disease.

      Today improved detection and treatments for Alzheimer disease are areas of concentrated scientific investigation. Early detection relies on the discovery of biomarkers (physiological changes specific to and indicative of a disease) and on the development of methods sensitive enough to measure these biomarkers. Several detection methods being developed for Alzheimer disease include blood tests to measure increased expression of a protein present in certain white blood cells and positron emission tomography to detect increased levels of an enzyme in cerebrospinal fluid. There are also a number of experimental drugs for Alzheimer disease in early- and late-stage clinical trials. One drug that has demonstrated some success in preventing cognitive decline in affected patients is tarenflurbil, a gamma-secretase modulator (sometimes referred to as a selective amyloid-beta-42-lowering agent). Tarenflurbil has been shown to reduce levels of amyloid-beta-42 protein, which is thought to be the primary amyloid protein involved in plaque formation. Another drug, methylthioninium chloride (Rember), more commonly known as methylene blue (an organic dye), targets the tau protein of neurofibrially tangles. In clinical trials, methylthioninium chloride either stopped or significantly slowed the progression of cognitive decline in patients with Alzheimer disease. It is the first drug capable of dissolving tau protein fibres and preventing the formation of neurofibrially tangles.

* * *


Universalium. 2010.

Look at other dictionaries:

  • Alzheimer disease — Alzheimer disease. См. болезнь Альцгеймера. (Источник: «Англо русский толковый словарь генетических терминов». Арефьев В.А., Лисовенко Л.А., Москва: Изд во ВНИРО, 1995 г.) …   Молекулярная биология и генетика. Толковый словарь.

  • Alzheimer disease — A progressive degenerative disease of the brain that leads to dementia. On a cellular level, Alzheimer disease is characterized by unusual helical protein filaments in nerve cells (neurons) of the brain. These odd twisted filaments are called… …   Medical dictionary

  • Alzheimer disease — A brain disorder that usually starts in late middle age or old age and gets worse over time. Symptoms include loss of memory, confusion, problems thinking, and changes in language, behavior, and personality. Also called Alzheimer dementia …   English dictionary of cancer terms

  • alzheimer disease — n. degenerative disease of the central nervous system which is characterized by dementia (mainly affects the elderly) …   English contemporary dictionary

  • Alzheimer Disease International — (ADI), was founded in 1984 to help to fight Alzheimer s disease that was first diagnosed back in 1906. In the present, ADI has grown as an international organization that also runs the Alzheimer University to help volunteers and staff of other… …   Wikipedia

  • Alzheimer Disease: Clues from Convents — ▪ 2002       An ongoing study of a highly cooperative group of long lived nuns has been shedding considerable light on aging and Alzheimer disease. The Nun Study, led by neurologist David Snowdon of the University of Kentucky, began in 1986 and… …   Universalium

  • Alzheimer disease (dementia) etc. — Alz·hei·mer disease (dementia), etc. (awltzґhi mər) [Alois Alzheimer, German neurologist, 1864–1915] see primary degenerative dementia, under dementia, and see under cell and disease, and at Stains and Staining Methods, under stain …   Medical dictionary

  • Depression of Alzheimer disease — Depression is one of the most common psychiatric symptoms in Alzheimer s disease, but it often appears in a different form than other depressive disorders. In 2002, a workgroup of the U.S. National Institute of Mental Health created a set of… …   Wikipedia

  • Alzheimer's disease — Alzheimer redirects here. For other uses, see Alzheimer (disambiguation). Alzheimer s disease Classification and external resources …   Wikipedia

  • Alzheimer's disease and hallucinations —    Alzheimer s disease is also known as senile dementia of the Alzheimer type (SDAT). Both eponyms refer to the German psychiatrist Alois Alzheimer (1864 1915), who in 1906 was the first to present post mortem histological findings associated… …   Dictionary of Hallucinations


Share the article and excerpts

Direct link
Do a right-click on the link above
and select “Copy Link”

We are using cookies for the best presentation of our site. Continuing to use this site, you agree with this.